Findings

What do systematic reviews say?

469 questions · 483 findings · 63 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 117 · 24.2%GRADE not reported 13 · 2.7%Very low 68 · 14.1%Low 141 · 29.2%Moderate 112 · 23.2%High 32 · 6.6%

Horticultural therapy plus standard care vs usual care

Level of functioning · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Horticultural therapy for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Cognitive behavioural therapy plus standard care vs control

Mental state · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)

1 finding from 1 review

Cognitive behavioural therapy added to standard care for first‐episode and recent‐onset psychosis 2024 · Cochrane Headline outcomes only
no estimate extracted
20 studies · 1508 participants
Low

Radiotherapy vs control

Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with neovascular AMD

Radiotherapy showed no clear difference in loss of 3 or more lines of best‐corrected visual acuity Measured… compared with control (low certainty).

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
RR 0.82 [0.64, 1.04]
Studies not reported
Low

Radiotherapy vs control

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with neovascular AMD

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Radiotherapy vs control

Contrast sensitivity (log contrast threshold) Measured using a Pelli‐Robson chart. Higher scores represent better contrast sensitivity. · people with neovascular AMD

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Radiotherapy vs control

New vessel growth Measured using fluorescein angiography or fundus photographs · people with neovascular AMD

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Radiotherapy vs control

Quality of life · people with neovascular AMD

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Radiotherapy vs control

Any adverse outcome · people with neovascular AMD

Radiotherapy may leads to lower any adverse outcome compared with control (low certainty).

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Radiotherapy vs control

Number of anti‐VEGF injections · people with neovascular AMD

The review found no eligible studies for this question.

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychological therapy vs usual care or attention control

General health · people with stroke

1 finding from 1 review

Pharmacological, psychological and non‐invasive brain stimulation interventions for preventing depression after stroke 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 240 participants
GRADE not reported

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 0.03 [0, 0.42]
1 study · 35 participants
Low

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 0.03 [0, 0.41]
1 study · 45 participants
Low

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 35 participants
Low

Sodium valproate vs phenytoin monotherapy

Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures

Sodium valproate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin monotherapy (low certainty).

1 finding from 1 review

Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.94 [0.55, 1.61]
5 studies · 341 participants
Low

Sodium valproate vs phenytoin monotherapy

Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures

Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin monotherapy (low certainty).

1 finding from 1 review

Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
HR 0.97 [0.72, 1.3]
5 studies · 395 participants
Low